| Abstract: |
Two phenotypes for 1-B-d-arabinofuranosylcytosine (ara-C) deamination corresponding to a ratio of distribution for "slow" (ratio, ≤14) vs "fast" (ratio, >14) deaminators of 70%:30%, have been determined on the basis of studies on plasma ratios of 1-B-d-arabinofuranosyluracil/ara-C (ara-U/ara-C) in 56 subjects treated with high-dose ara-C (3 g/m2 infused i.v. over 3 h). A positive correlation of age with the concentration of ara-U was observed. In a subgroup of 36 patients with leukemia, the ara-U/ara-C pattern was similar to that observed for all 56 subjects. In these leukemic patients, who were treated with combinations of ara-C plus other conventional agents, a tendency toward a positive response (complete response +partial response) was found for those showing low ara-U/ara-C ratios (slow deaminators). The phenotypic effect of deamination in acute leukemia needs to be evaluated prospectively. © 1992 Springer-Verlag. |
| Keywords: |
adolescent; adult; controlled study; aged; aged, 80 and over; leukemia; major clinical study; drug efficacy; cytarabine; phenotype; dose-response relationship, drug; age; deamination; lymphoma; uracil arabinoside; arabinofuranosyluracil; serum albumin, bovine; drug metabolism; drug blood level; leukocyte count; drug metabolite; sex factors; intravenous drug administration; pharmacology; middle age; leukemia, myelocytic, acute; leukemia, myeloid, chronic; leukemia, lymphocytic, acute; human; male; female; priority journal; article; support, non-u.s. gov't
|
